Research progress on influencing factors of drug resistance of carbapenem-resistant <i>Klebsiella pneumoniae</i>_West China Medical Journal

Authors：

TAN Shengtong ¹ , ZHANG Xinping ² ,  CHEN Xiuwen ²

1. School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang 330006, P. R. China;
2. Department of Nosocomial Infection Control, Jiangxi Children’s Hospital, Nanchang 330066, P. R. China;

Corresponding author：

CHEN Xiuwen, Email: wen8023@126.com

Keywords：

Carbapenem-resistant Klebsiella pneumoniae; resistance mechanism; drug resistance; influencing factor

DOI：

10.7507/1002-0179.202302148

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, with the wide application of carbapenems, the resistance of Enterobacterium to carbapenems has become increasingly high, leading to a large number of carbapenem-resistant Klebsiella pneumoniae (CRKP). These bacteria are often resistant to many different types of antibacterial drugs, including carbapenems, which leads to clinical treatment failure and seriously threatens the life safety of patients. Currently, these bacteria have become an independent risk factor for patients’ death. This article reviews the drug resistance, infection status and influencing factors, and medication therapy of CRKP, in order to facilitate the clinical diagnosis, treatment, and disease process control of CRKP infection, and provide reference for curbing bacterial drug resistance.

Citation： TAN Shengtong, ZHANG Xinping, CHEN Xiuwen. Research progress on influencing factors of drug resistance of carbapenem-resistant Klebsiella pneumoniae. West China Medical Journal, 2023, 38(3): 459-464. doi: 10.7507/1002-0179.202302148 Copy

1.	Soares de Moraes L, Gomes Magalhaes GL, Material Soncini JG, et al. High mortality from carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Microb Pathog, 2022, 167: 105519.
2.	康蓓佩, 付晓蕊, 贺文芳, 等. 耐碳青霉烯类的肺炎克雷伯菌的感染特点及耐药基因分析. 国际检验医学杂志, 2019, 40(24): 2991-2994, 2998.
3.	杨沙沙, 王喜仁, 韩杰, 等. 美国 CLSI 抗菌药物敏感试验操作标准(2010 年版)部分变更内容. 中国感染控制杂志, 2010, 9(4): 303-304.
4.	Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis, 2017, 215(Suppl_1): S28-S36.
5.	Oteo J, Pérez-Vázquez M, Bautista V, et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother, 2016, 71(12): 3392-3399.
6.	Liao W, Liu Y, Zhang W. Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: a review over the last 10 years. J Glob Antimicrob Resist, 2020, 23: 174-180.
7.	Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol, 2013, 4: 48.
8.	禹明均, 郑小鹏, 李春江. 耐碳青霉烯类肺炎克雷伯菌耐药机制的研究进展. 现代盐化工, 2022, 49(3): 13-15.
9.	许晓娜, 王志盛, 张小倩, 等. 耐碳青霉烯类肺炎克雷伯菌耐药机制的研究进展. 河南医学研究, 2018, 27(17): 3125-3126.
10.	Ho PL, Cheung YY, Wang Y, et al. Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong Kong. Eur J Clin Microbiol Infect Dis, 2016, 35(3): 379-385.
11.	王芬芳, 杨坤祥, 徐华. 新生儿医院感染肺炎克雷伯菌的耐药性分析. 国际检验医学杂志, 2017, 38(1): 107-109.
12.	赵容陶, 娜木罕, 朝宝, 等. 新生儿肺炎克雷伯菌败血症的临床特征及耐药性分析. 中国妇幼健康研究, 2022, 33(6): 96-102.
13.	杜逸亭, 胡旭红, 杨晓荣, 等. 新生儿肺炎克雷伯菌败血症临床特点和药敏分析. 四川医学, 2017, 38(12): 1420-1423.
14.	2020 年全国细菌耐药监测报告. 中国合理用药探索, 2022, 19(11): 83.
15.	郝东侠, 王彦宏, 王旭东. 医院获得性耐碳青霉烯肺炎克雷伯杆菌感染的特点、危险因素分析及预后. 中国临床医生杂志, 2019, 47(5): 522-525.
16.	Pellegrini JL, Aguirre C, Soto SM, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from a pediatric hospital from Corrientes, Argentina. Rev Chilena Infectol, 2022, 39(2): 109-116.
17.	Candevir Ulu A, Güven Gökmen T, Kibar F, et al. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae at a Turkish centre: is the increase of resistance a threat for Europe?. J Glob Antimicrob Resist, 2017, 11: 10-16.
18.	Ghamari M, Beigverdi R, Jabalameli F, et al. Antimicrobial resistance pattern, virulence determinants and molecular analysis of carbapenem-resistant Klebsiella pneumoniae isolated from clinical samples in Iran. FEMS Microbiol Lett, 2022, 369(1): fnac100.
19.	Chen IR, Huang PH, Wu PF, et al. Clinical characteristics and outcomes of 56 patients with pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2021, 25: 326-330.
20.	Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents, 2022, 60(5/6): 106679.
21.	Tesfa T, Mitiku H, Edae M, et al. Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis. Syst Rev, 2022, 11(1): 240.
22.	Ahmed El-Domany R, El-Banna T, Sonbol F, et al. Co-existence of NDM-1 and OXA-48 genes in carbapenem resistant Klebsiella pneumoniae clinical isolates in Kafrelsheikh, Egypt. Afr Health Sci, 2021, 21(2): 489-496.
23.	Thapa S, Adhikari N, Shah AK, et al. Detection of NDM-1 and VIM genes in carbapenem-resistant Klebsiella pneumoniae isolates from a tertiary health-care center in Kathmandu, Nepal. Chemotherapy, 2021, 66(5/6): 199-209.
24.	Berglund B, Hoang NTB, Lundberg L, et al. Clonal spread of carbapenem-resistant Klebsiella pneumoniae among patients at admission and discharge at a Vietnamese neonatal intensive care unit. Antimicrob Resist Infect Control, 2021, 10(1): 162.
25.	Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis, 2014, 20(7): 1170-1175.
26.	Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob, 2017, 16(1): 18.
27.	Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev, 2016, 80(3): 629-661.
28.	Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol, 2018, 8: 4.
29.	Gomez-Simmonds A, Uhlemann AC. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J Infect Dis, 2017, 215(Suppl_1): S18-S27.
30.	Arato V, Raso MM, Gasperini G, et al. Prophylaxis and treatment against Klebsiella pneumoniae: current insights on this emerging anti-microbial resistant global threat. Int J Mol Sci, 2021, 22(8): 4042.
31.	Han R, Niu M, Liu S, et al. The effect of siderophore virulence genes entB and ybtS on the virulence of carbapenem-resistant Klebsiella pneumoniae. Microb Pathog, 2022, 171: 105746.
32.	于新桥. 早产儿败血症临床治疗中碳青霉烯类和 β-内酰胺类药物的使用与耐药性分析. 检验医学与临床, 2017, 14(7): 1021-1024.
33.	Ruiz J, Gordon M, Villarreal E, et al. Influence of antibiotic pressure on multi-drug resistant Klebsiella pneumoniae colonisation in critically ill patients. Antimicrob Resist Infect Control, 2019, 8: 38.
34.	Li M, Yang S, Yao H, et al. Retrospective analysis of epidemiology, risk factors, and outcomes of health care-acquired carbapenem-resistant Klebsiella pneumoniae bacteremia in a Chinese tertiary hospital, 2010-2019. Infect Dis Ther, 2023, 12(2): 473-485.
35.	Qian Y, Bi Y, Liu S, et al. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med, 2021, 10(7): 7340-7350.
36.	Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist, 2018, 24(2): 190-198.
37.	Yuan Y, Wang J, Yao Z, et al. Risk Factors for carbapenem-Resistant Klebsiella pneumoniae bloodstream infections and outcomes. Infect Drug Resist, 2020, 13: 207-215.
38.	Lu J, Zhang A, Han L, et al. Clinical outcomes and risk factors for death following carbapenem-resistant Klebsiella pneumoniae infection in solid organ transplant recipients. Microbiol Spectr, 2023, 11(1): e0475522.
39.	Manandhar S, Amatya P, Ansari I, et al. Risk factors for the development of neonatal sepsis in a neonatal intensive care unit of a tertiary care hospital of Nepal. BMC Infect Dis, 2021, 21(1): 546.
40.	Akgul F, Bozkurt I, Sunbul M, et al. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: case control study. Pathog Glob Health, 2016, 110(7/8): 321-325.
41.	Qin X, Wu S, Hao M, et al. The colonization of carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China. J Infect Dis, 2020, 221(Suppl 2): S206-S214.
42.	Ding Y, Wang Y, Hsia Y, et al. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob, 2019, 18(1): 36.
43.	陈虹宇, 黄双双, 孙丽芳, 等. 儿童检出耐碳青霉烯类肺炎克雷伯菌的影响因素分析. 检验医学与临床, 2021, 18(2): 168-171.
44.	方清永, 李迎丽, 邱景富. ICU 耐碳青霉烯类肺炎克雷伯菌医院获得性肺炎危险因素分析. 国际检验医学杂志, 2017, 38(19): 2663-2665.
45.	Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colomb Med (Cali), 2014, 45(2): 54-60.
46.	孙武铭, 周华, 马文江, 等. 碳青霉烯耐药肺炎克雷伯杆菌血流感染不同治疗方案疗效和安全性分析//2018 年（第四十届）浙江省医学会呼吸系病学术年会. 杭州: 浙江省科学技术协会, 2018: 26-32.
47.	Ni W, Yang D, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother, 2021, 76(8): 2097-2105.
48.	Balkan II, Alkan M, Aygün G, et al. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis, 2021, 40(10): 2161-2170.
49.	龙晓琴, 方丽. 耐碳青霉烯类肺炎克雷伯杆菌感染的研究进展. 疑难病杂志, 2021, 20(12): 1282-1286.
50.	Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis, 2020, 7: 2049936120912049.
51.	应颖秋, 张哲浩, 程吟楚, 等. 北京市 70 家医院重症监护病房碳青霉烯类抗菌药物及替加环素应用的横断面研究. 中国医院药学杂志, 2019, 39(20): 2035-2039.
52.	Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(11): e3126.
53.	Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis, 2011, 11(11): 834-844.
54.	Dhandapani S, Sistla S, Gunalan A, et al. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Indian J Med Microbiol, 2021, 39(1): 6-10.
55.	张莉, 胡淼, 陈媛, 等. 耐碳青霉烯类肺炎克雷伯杆菌肺部感染患者不同抗菌药物联合治疗方案的疗效与安全性分析. 药学与临床研究, 2022, 30(4): 315-318.
56.	van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road?. J Clin Microbiol, 2015, 53(10): 3116-3117.
57.	Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev, 2012, 25(4): 682-707.
58.	Shields RK, Clancy CJ, Press EG, et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother, 2016, 60(5): 3187-3192.
59.	Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-817.
60.	黄娟娟, 何鸽飞, 易爱纯, 等. 磷霉素联合依替米星治疗耐碳青霉烯肺炎克雷伯菌重症感染的疗效. 中南药学, 2017, 15(10): 1484-1487.
61.	史少明, 王明月, 梁文炎, 等. 头孢他啶/阿维巴坦治疗耐碳青霉烯类肺炎克雷伯杆菌感染的疗效及影响因素分析. 医学研究生学报, 2022, 35(11): 1190-1195.
62.	姜婷, 邓飞, 恽波. 头孢他啶-阿维巴坦治疗耐碳青霉烯肺炎克雷伯菌肺部感染的疗效. 江苏医药, 2020, 46(12): 1286-1288.
63.	van Duin D, Lok J. J, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis, 2018, 66(2): 163-171.
64.	Findlay J, Poirel L, Juhas M, et al. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother, 2021, 65(9): e0089021.
65.	Han X, Shi Q, Mao Y, et al. Emergence of ceftazidime/avibactam and tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae due to in-host microevolution. Front Cell Infect Microbiol, 2021, 11: 757470.

1. Soares de Moraes L, Gomes Magalhaes GL, Material Soncini JG, et al. High mortality from carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Microb Pathog, 2022, 167: 105519.
2. 康蓓佩, 付晓蕊, 贺文芳, 等. 耐碳青霉烯类的肺炎克雷伯菌的感染特点及耐药基因分析. 国际检验医学杂志, 2019, 40(24): 2991-2994, 2998.
3. 杨沙沙, 王喜仁, 韩杰, 等. 美国 CLSI 抗菌药物敏感试验操作标准(2010 年版)部分变更内容. 中国感染控制杂志, 2010, 9(4): 303-304.
4. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis, 2017, 215(Suppl_1): S28-S36.
5. Oteo J, Pérez-Vázquez M, Bautista V, et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother, 2016, 71(12): 3392-3399.
6. Liao W, Liu Y, Zhang W. Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: a review over the last 10 years. J Glob Antimicrob Resist, 2020, 23: 174-180.
7. Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol, 2013, 4: 48.
8. 禹明均, 郑小鹏, 李春江. 耐碳青霉烯类肺炎克雷伯菌耐药机制的研究进展. 现代盐化工, 2022, 49(3): 13-15.
9. 许晓娜, 王志盛, 张小倩, 等. 耐碳青霉烯类肺炎克雷伯菌耐药机制的研究进展. 河南医学研究, 2018, 27(17): 3125-3126.
10. Ho PL, Cheung YY, Wang Y, et al. Characterization of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from a healthcare region in Hong Kong. Eur J Clin Microbiol Infect Dis, 2016, 35(3): 379-385.
11. 王芬芳, 杨坤祥, 徐华. 新生儿医院感染肺炎克雷伯菌的耐药性分析. 国际检验医学杂志, 2017, 38(1): 107-109.
12. 赵容陶, 娜木罕, 朝宝, 等. 新生儿肺炎克雷伯菌败血症的临床特征及耐药性分析. 中国妇幼健康研究, 2022, 33(6): 96-102.
13. 杜逸亭, 胡旭红, 杨晓荣, 等. 新生儿肺炎克雷伯菌败血症临床特点和药敏分析. 四川医学, 2017, 38(12): 1420-1423.
14. 2020 年全国细菌耐药监测报告. 中国合理用药探索, 2022, 19(11): 83.
15. 郝东侠, 王彦宏, 王旭东. 医院获得性耐碳青霉烯肺炎克雷伯杆菌感染的特点、危险因素分析及预后. 中国临床医生杂志, 2019, 47(5): 522-525.
16. Pellegrini JL, Aguirre C, Soto SM, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from a pediatric hospital from Corrientes, Argentina. Rev Chilena Infectol, 2022, 39(2): 109-116.
17. Candevir Ulu A, Güven Gökmen T, Kibar F, et al. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae at a Turkish centre: is the increase of resistance a threat for Europe?. J Glob Antimicrob Resist, 2017, 11: 10-16.
18. Ghamari M, Beigverdi R, Jabalameli F, et al. Antimicrobial resistance pattern, virulence determinants and molecular analysis of carbapenem-resistant Klebsiella pneumoniae isolated from clinical samples in Iran. FEMS Microbiol Lett, 2022, 369(1): fnac100.
19. Chen IR, Huang PH, Wu PF, et al. Clinical characteristics and outcomes of 56 patients with pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2021, 25: 326-330.
20. Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents, 2022, 60(5/6): 106679.
21. Tesfa T, Mitiku H, Edae M, et al. Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: systematic review and meta-analysis. Syst Rev, 2022, 11(1): 240.
22. Ahmed El-Domany R, El-Banna T, Sonbol F, et al. Co-existence of NDM-1 and OXA-48 genes in carbapenem resistant Klebsiella pneumoniae clinical isolates in Kafrelsheikh, Egypt. Afr Health Sci, 2021, 21(2): 489-496.
23. Thapa S, Adhikari N, Shah AK, et al. Detection of NDM-1 and VIM genes in carbapenem-resistant Klebsiella pneumoniae isolates from a tertiary health-care center in Kathmandu, Nepal. Chemotherapy, 2021, 66(5/6): 199-209.
24. Berglund B, Hoang NTB, Lundberg L, et al. Clonal spread of carbapenem-resistant Klebsiella pneumoniae among patients at admission and discharge at a Vietnamese neonatal intensive care unit. Antimicrob Resist Infect Control, 2021, 10(1): 162.
25. Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis, 2014, 20(7): 1170-1175.
26. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob, 2017, 16(1): 18.
27. Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev, 2016, 80(3): 629-661.
28. Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol, 2018, 8: 4.
29. Gomez-Simmonds A, Uhlemann AC. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J Infect Dis, 2017, 215(Suppl_1): S18-S27.
30. Arato V, Raso MM, Gasperini G, et al. Prophylaxis and treatment against Klebsiella pneumoniae: current insights on this emerging anti-microbial resistant global threat. Int J Mol Sci, 2021, 22(8): 4042.
31. Han R, Niu M, Liu S, et al. The effect of siderophore virulence genes entB and ybtS on the virulence of carbapenem-resistant Klebsiella pneumoniae. Microb Pathog, 2022, 171: 105746.
32. 于新桥. 早产儿败血症临床治疗中碳青霉烯类和 β-内酰胺类药物的使用与耐药性分析. 检验医学与临床, 2017, 14(7): 1021-1024.
33. Ruiz J, Gordon M, Villarreal E, et al. Influence of antibiotic pressure on multi-drug resistant Klebsiella pneumoniae colonisation in critically ill patients. Antimicrob Resist Infect Control, 2019, 8: 38.
34. Li M, Yang S, Yao H, et al. Retrospective analysis of epidemiology, risk factors, and outcomes of health care-acquired carbapenem-resistant Klebsiella pneumoniae bacteremia in a Chinese tertiary hospital, 2010-2019. Infect Dis Ther, 2023, 12(2): 473-485.
35. Qian Y, Bi Y, Liu S, et al. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med, 2021, 10(7): 7340-7350.
36. Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist, 2018, 24(2): 190-198.
37. Yuan Y, Wang J, Yao Z, et al. Risk Factors for carbapenem-Resistant Klebsiella pneumoniae bloodstream infections and outcomes. Infect Drug Resist, 2020, 13: 207-215.
38. Lu J, Zhang A, Han L, et al. Clinical outcomes and risk factors for death following carbapenem-resistant Klebsiella pneumoniae infection in solid organ transplant recipients. Microbiol Spectr, 2023, 11(1): e0475522.
39. Manandhar S, Amatya P, Ansari I, et al. Risk factors for the development of neonatal sepsis in a neonatal intensive care unit of a tertiary care hospital of Nepal. BMC Infect Dis, 2021, 21(1): 546.
40. Akgul F, Bozkurt I, Sunbul M, et al. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: case control study. Pathog Glob Health, 2016, 110(7/8): 321-325.
41. Qin X, Wu S, Hao M, et al. The colonization of carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China. J Infect Dis, 2020, 221(Suppl 2): S206-S214.
42. Ding Y, Wang Y, Hsia Y, et al. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob, 2019, 18(1): 36.
43. 陈虹宇, 黄双双, 孙丽芳, 等. 儿童检出耐碳青霉烯类肺炎克雷伯菌的影响因素分析. 检验医学与临床, 2021, 18(2): 168-171.
44. 方清永, 李迎丽, 邱景富. ICU 耐碳青霉烯类肺炎克雷伯菌医院获得性肺炎危险因素分析. 国际检验医学杂志, 2017, 38(19): 2663-2665.
45. Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colomb Med (Cali), 2014, 45(2): 54-60.
46. 孙武铭, 周华, 马文江, 等. 碳青霉烯耐药肺炎克雷伯杆菌血流感染不同治疗方案疗效和安全性分析//2018 年（第四十届）浙江省医学会呼吸系病学术年会. 杭州: 浙江省科学技术协会, 2018: 26-32.
47. Ni W, Yang D, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother, 2021, 76(8): 2097-2105.
48. Balkan II, Alkan M, Aygün G, et al. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis, 2021, 40(10): 2161-2170.
49. 龙晓琴, 方丽. 耐碳青霉烯类肺炎克雷伯杆菌感染的研究进展. 疑难病杂志, 2021, 20(12): 1282-1286.
50. Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis, 2020, 7: 2049936120912049.
51. 应颖秋, 张哲浩, 程吟楚, 等. 北京市 70 家医院重症监护病房碳青霉烯类抗菌药物及替加环素应用的横断面研究. 中国医院药学杂志, 2019, 39(20): 2035-2039.
52. Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(11): e3126.
53. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis, 2011, 11(11): 834-844.
54. Dhandapani S, Sistla S, Gunalan A, et al. In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E. coli and Klebsiella pneumoniae by checkerboard method. Indian J Med Microbiol, 2021, 39(1): 6-10.
55. 张莉, 胡淼, 陈媛, 等. 耐碳青霉烯类肺炎克雷伯杆菌肺部感染患者不同抗菌药物联合治疗方案的疗效与安全性分析. 药学与临床研究, 2022, 30(4): 315-318.
56. van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road?. J Clin Microbiol, 2015, 53(10): 3116-3117.
57. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev, 2012, 25(4): 682-707.
58. Shields RK, Clancy CJ, Press EG, et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother, 2016, 60(5): 3187-3192.
59. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-817.
60. 黄娟娟, 何鸽飞, 易爱纯, 等. 磷霉素联合依替米星治疗耐碳青霉烯肺炎克雷伯菌重症感染的疗效. 中南药学, 2017, 15(10): 1484-1487.
61. 史少明, 王明月, 梁文炎, 等. 头孢他啶/阿维巴坦治疗耐碳青霉烯类肺炎克雷伯杆菌感染的疗效及影响因素分析. 医学研究生学报, 2022, 35(11): 1190-1195.
62. 姜婷, 邓飞, 恽波. 头孢他啶-阿维巴坦治疗耐碳青霉烯肺炎克雷伯菌肺部感染的疗效. 江苏医药, 2020, 46(12): 1286-1288.
63. van Duin D, Lok J. J, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis, 2018, 66(2): 163-171.
64. Findlay J, Poirel L, Juhas M, et al. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother, 2021, 65(9): e0089021.
65. Han X, Shi Q, Mao Y, et al. Emergence of ceftazidime/avibactam and tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae due to in-host microevolution. Front Cell Infect Microbiol, 2021, 11: 757470.

West China Medical Journal

Research progress on influencing factors of drug resistance of carbapenem-resistant Klebsiella pneumoniae

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content